Assessing the Effectiveness of Montelukast Sodium in Managing Pulmonary Infections in Lung Cancer Patients

Abstract

Objective: To investigate the efficacy of montelukast sodium in the treatment of lung cancer patients with pulmonary infections. Methods: A total of 330 patients diagnosed with lung cancer and pulmonary infection, who were admitted to the First Affiliated Hospital of Xi’an Medical University from 2020 to 2022, were selected as research subjects. They were randomly divided into two groups: a control group receiving conventional treatment and an observation group receiving conventional treatment combined with montelukast sodium. Each group consisted of 165 cases. The time required for clinical symptom improvement, the resolution of lung infection signs, and the levels of serum inflammatory factors before and after treatment were compared between the two groups. Results: The observation group exhibited significantly faster improvement in clinical symptoms compared to the control group (P < 0.001). ELISA assays were conducted to detect the expression levels of IL-1β, IL-6, IL-8, and TNF-α in the serum of both groups at 1 week and 2 weeks into the treatment. The results indicated that, as the treatment progressed, the observation group displayed significantly lower levels of the four serum inflammatory factors compared to the control group (P < 0.001). Conclusion: Montelukast sodium demonstrates efficacy in the treatment of patients with lung cancer complicated by pulmonary infections. These findings suggest its potential for further verification and clinical application.